Were this to prove true, I would expect some sells to even out per-spilt averaging down that has been done by retail investors.
Without evidence of Canada sales volume to direct use customers, I am wondering how any useful data can be derived without a Canada Clinical Trial supported by professional medical staff ( and feed-back from druggists).
Nothing has come out yet on this scenario, nor any known clinical testing and recommendations by USA professional medical centers and user support organizations.
This is puzzling (to me at least), in that DRIO has made no public statement on status of its USA FDA initial contact for review meetings. <---therefore, i am hands-up-in-the-air about this kind of PR effect on stock price happening in first six months of 2015.
It is not conducive to retail investors confidence to continue stock buying, when important dates are pushed off another 6 months and fluff PRs come out about new hires.
And, do not keep telling us 'wonderful things' are coming in 2015 . . . unless company is willing to present evidence of new R&D, marketing, and sales revenues. ,---If this type ofthing continues . . . it would seem to indicate a company in 'struggling' stage.
Who really thinking DRIO has 1 to 2 years available to get its act together . . . without competitors entering the same market space? Goggle, Amazon, Samsung . . . and even MSFT and other phone manufacturers are 'hot' to achieve new mobile sector appls and devices sector potential (read: mobile medical devices sales).
Carbon Taxes (as way to gain new taxation by increasing retail price of petro) is a done deal for both parties and administration; regardless of what ensues in ME, etc.
USA is 'broke' and needs to stimulate employment, infrastructure, and tech efficiency . . . thus new Carbon Taxes for everyone to pay AND passage of bill to allow overseas USA, etc. Multinationals to return-invest in USA plants and hirings TAX-FREE. <---question is . . . can DRIO be product ready commerically for this event?
